Highnoon

Un-audited
Financial Statements
For the 3rd Quarter
Ended 30 September 2026



Enriching Life





Contents

Company Information	2
Directors' Report ڈائریکٹرز رپورٹ	4-9
Condensed Interim Un-Consolidated Financial Statements	10
Condensed Interim Un-Consolidated Statement of Financial Position	11-12
Condensed Interim Un-Consolidated Statement of Profit or Loss	13
Condensed Interim Un-Consolidated Statement of Comprehensive Income	14
Condensed Interim Un-Consolidated Statement of Cash Flows	15
Condensed Interim Un-Consolidated Statement of Changes in Equity	16
Selected Notes to the Condensed Interim Un-consolidated Financial Statements	17
Condensed Interim Consolidated Financial Statements	37
Condensed Interim Consolidated Statement of Financial Position	38-39
Condensed Interim Consolidated Statement of Profit or Loss	40
Condensed Interim Consolidated Statement of Comprehensive Income	41
Condensed Interim Consolidated Statement of Cash Flows	42
Condensed Interim Consolidated Statement of Changes in Equity	43
Selected Notes to the Condensed Interim Consolidated Financial Statements	44

Company Information

Board of Directors
Tariq Wajid
Chairman

Dr. Adeel Abbas Haideri
Chief Executive Officer

Tausif Ahmad Khan
Director

Tehmina Saeed Chaudhury
Director

Taufiq Ahmed Khan
Director

Tauqir Ahmed Khan
Director

Dr. Aman Ullah Khan
Director

Chief Financial Officer
Ashfaq Alidina

Senior General Counsel & Company Secretary
Baqar Hasan

Head Internal Auditor
Rizwan Shahid

Registered Office and Plant
17.5 Kilometer Multan Road,
Lahore - 53700, Pakistan
UAN:+92 42 111 000 465
Fax : +92 42 3751 0037
E-mail :
corporate.affairs@highnoon.com.pk;
investor.relations@highnoon.com.pk
Web : www.highnoon-labs.com

Corporate Office
901-9th floor, Tricon Corporate Center
73-E, Jail Road, Lahore
UAN : +92 304 111 0465
Ph:+92 42 35158051-2

Legal Advisor
Raja Muhammad Akram & Co.

Tax Advisor
Yousuf Islam & Associates

Auditors
BDO Ebrahim & Co. Chartered Accountants

Shares Registrar
Corplink (Pvt.) Ltd.
Wings Arcade,
1-K Commercial,
Model Town, Lahore.
Tel: +92 42 3591 6714, 3591 6719
Fax: + 92 42 3586 9037

Bankers
Allied Bank Limited
Askari Bank Limited
Bank AL Habib Limited
Bank Alfalah Limited
Bank Makramah Limited (formerly Summit Bank Limited)
BankIslami Pakistan Limited
Dubai Islamic Bank Limited
Faysal Bank Limited
First Habib Modaraba
Habib Bank Limited
Habib Metropolitan Bank Limited
JS Bank Limited
MCB Bank Limited
Meezan Bank Limited
Mobilink Microfinance Bank Limited
National Bank of Pakistan Limited
Soneri Bank Limited
Standard Chartered Bank Limited
The Bank of Punjab
United Bank Limited

Board and Management Committees

Audit Committee

Dr. Aman Ullah Khan	Chairperson
Tariq Wajid	Member
Tehmina Saeed Chaudhury	Member
Tauqir Ahmed Khan	Member

Human Resources and Remuneration Committee

Tariq Wajid	Chairperson
Dr. Adeel Abbas Haideri	Member
Tehmina Saeed Chaudhury	Member
Taufiq Ahmed Khan	Member

Sustainability Committee

Tehmina Saeed Chaudhury	Chairperson
Dr. Adeel Abbas Haideri	Member
Tauqir Ahmed Khan	Member

Risk Management Committee

Tariq Wajid	Chairperson
Dr. Adeel Abbas Haideri	Member
Taufiq Ahmed Khan	Member
Dr. Aman Ullah Khan	Member

Nomination Committee

Tausif Ahmad Khan	Chairperson
Taufiq Ahmed Khan	Member
Tehmina Saeed Chaudhury	Member

Executive Committee

Dr. Adeel Abbas Haideri	Chairperson
Dr. Shahzad Khan	Member
Taufiq Ahmed Khan	Member
Aamir Zafar	Member
Ashfaq Alidina	Member
Dr. Azfar Abbas Haidrie	Member
Syed Zulfiqar Ali Zaidi	Member
Shahnawaz Baig	Member

I.T Steering Committee

Taufiq Ahmed Khan	Chairperson
Dr. Adeel Abbas Haideri	Member
Ashfaq Alidina	Member
Syed Zulfiqar Ali Zaidi	Member
Shahnawaz Baig	Member
Farhan Iftikhar Hashmi	Member

Directors' Report to the Shareholders

The Directors of Highnoon Laboratories Limited (the "Company" or "Highnoon") are pleased to present their report, together with the un-audited condensed interim financial statements of your Company and the Group for the nine months ended on September 30, 2026.

As one of Pakistan's established healthcare companies, your Company remains committed to enhancing lives and patient care through the manufacturing, import, sale, and marketing of pharmaceutical and allied healthcare products.

FINANCIAL HIGHLIGHTS

Net sales increased by 3.8% compared with the corresponding period of 2025. This growth was driven by a favourable product mix, higher volumes, and improved price realisation, and was further supported by portfolio diversification and a strengthened market position. In absolute terms, gross profit rose by 5.1% over the same period, with the gross margin improving from 55% to 56%.

Notwithstanding persistent industry headwinds, the Company maintained its focus on operational efficiency, benefited from regulatory price adjustments, and leveraged market intelligence to mitigate cost pressures and sustain its business performance. As a result, the operating margin improved from 21% to 22%, an increase of 100 basis points. However, these gains were offset by a higher effective tax rate, and profit after tax remained broadly unchanged compared with the corresponding period last year.

The Company continues to perform ahead of expectations and to make strong progress towards its strategic milestones.

The financial performance of the Company during the nine months ended September 30, 2026, is as follows:

Key Financial Highlights	September 2026	September 2025
	(Rupees in Millions)	
Sales	19,324	18,615
Gross Profit	10,764	10,240
Gross Profit %	56%	55%
Operating Profit	4,325	3,880
Operating Profit %	22%	21%
Finance Cost	(65)	(91)
Other Income	345	333
Profit before tax & levy	4,605	4,122
Tax & levy	(1,984)	(1493)
Profit after tax & levy	2,621	2,628

EARNINGS PER SHARE

Based on condensed interim financial statements for nine months ended September 30, 2026, Highnoon's Earnings Per Share (EPS) has landed at Rs. 49.47 (2025: 49.61).

GROUP PERFORMANCE

The Directors are pleased to present the unaudited Condensed Interim Consolidated Financial Statements of Highnoon Laboratories Limited the ("Holding Company") and Curexa Health (Private) Limited its wholly owned Subsidiary company ("the Subsidiary") together mentioned as ("the Group") for the nine months ended September 30, 2026.

The summarized financial performance of the Group during the nine months ended September 30, 2026, under review, is as follows:

Key Financial Highlights	September 2026	September 2025
	(Rupees in Millions)	
Profit before tax and levy	4,731	4,238
Tax & levy	(2,017)	(1,558)
Profit after tax and levy	2,714	2,681
Earnings Per Share (Rs.)	51.22	50.59

FUTURE OUTLOOK

Pakistan's economic outlook reflects cautious optimism, supported by improving macroeconomic stability, fiscal consolidation, and favourable developments in the external sector. Sustaining this progress and unlocking the country's long-term growth potential will require continued structural reform and policy consistency. The regulatory environment for the healthcare and pharmaceutical sectors, however, remains complex and continues to evolve. A transparent, predictable, and streamlined regulatory framework is essential to attracting investment, fostering innovation, and enabling the industry to play a greater role in improving national healthcare outcomes.

Against this backdrop, Highnoon remains focused on sustainable growth and profitability through operational excellence, prudent cost management, portfolio diversification, and expansion into new markets. The Company will continue to adapt to changing market dynamics, strengthen its competitive position, and pursue growth opportunities, while maintaining financial discipline and its long-term commitment to creating value for its shareholders and other stakeholders.

ACKNOWLEDGMENT

The Board of Directors sincerely thanks all employees for their steadfast dedication throughout the period. We also express our appreciation to our shareholders, customers, and partners for their continued trust and collaboration, which have been instrumental in advancing our strategic goals and sustaining growth. Moving forward, we remain steadfast in upholding the highest standards of corporate governance and delivering enduring value to all stakeholders.

For, and on behalf of the Board

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Lahore: October 27, 2026

اظہارِ تشکر

بورڈ آف ڈائریکٹرز اپنے تمام ملازمین کا دل سے شکریہ ادا کرتا ہے جنہوں نے پورے سہ ماہی کے دوران اپنی غیر متزلزل لگن اور عزم کا مظاہرہ کیا۔ ہم اپنے شیئر ہولڈرز، صارفین اور شراکت داروں کے قیمتی تعاون کا بھی شکریہ ادا کرتے ہیں جن کے اعتماد اور شراکت نے ہماری اسٹریٹجک مقاصد اور پائیدار ترقی کو آگے بڑھانے میں اہم کردار ادا کیا۔ آئندہ کی جانب، ہم کارپوریٹ گورننس کے اعلیٰ ترین معیارات کو برقرار رکھنے اور اپنے تمام اسٹیک ہولڈرز کے لیے طویل مدتی قدر فراہم کرنے کے لیے پرعزم ہیں۔

منجانب بورڈ آف ڈائریکٹرز

ڈاکٹر عدیل عباس حیدری
چیف ایگزیکٹو آفیسر
لاہور: 27 اکتوبر 2026

توفیق احمد خان
ڈائریکٹر

فی شیئر آمدنی

30 ستمبر 2026 کو ختم ہونے والی نو ماہ کی مدت کے مختصر عبوری مالیاتی گوشواروں کے مطابق، ہائی نون کی فی شیئر آمدنی 49.47 روپے رہی، جبکہ 2025 کی اسی مدت میں یہ 49.61 روپے تھی۔

گروپ کی کارکردگی

ڈائریکٹرز کو خوشی محسوس ہو رہی ہے کہ وہ ہائی نون لیبارٹریز لمیٹڈ ("ہولڈنگ کمپنی") اور اس کی مکمل ملکیتی ذیلی کمپنی کیوریکسا ہیلتھ (پرائیویٹ) لمیٹڈ ("ذیلی کمپنی")، جنہیں مجموعی طور پر ("گروپ") کہا جاتا ہے، کی غیر آڈٹ شدہ جامع عبوری مالیاتی بیانات 30 ستمبر 2026 کو ختم ہونے والے نو ماہی لیے پیش کر رہے ہیں۔

30 ستمبر 2026 کو ختم ہونے والے نو ماہ کیلئے گروپ کی مالی کارکردگی کا خلاصہ کے درج ذیل ہے۔

مالی کارکردگی	30 ستمبر 2026	30 ستمبر 2025
	روپے (000,000)	
قبل از ٹیکس اور لیوی منافع	4,731	4,238
ٹیکس اور لیوی	(2,017)	(1,558)
بعد از ٹیکس منافع	2,714	2,681
فی شیئر آمدنی	51.22	50.59

مستقبل پر ایک نظر

پاکستان کا معاشی منظر نامہ محتاط اندازے کے مطابق امید افزا نظر آتا ہے، جسے معاشی استحکام میں بہتری، مالیاتی استحکام کے لیے اقدامات اور بیرونی شعبے میں مثبت پیش رفت سے تقویت مل رہی ہے۔ اس پیش رفت کو برقرار رکھنے اور ملک کی طویل مدتی ترقی کی صلاحیت کو بروئے کار لانے کے لیے مسلسل ساختی اصلاحات اور پالیسیوں میں تسلسل ضروری ہوگا۔ تاہم، صحت اور ادویہ سازی کے شعبوں کے لیے ضابطہ جاتی ماحول بدستور پیچیدہ ہے اور مسلسل تبدیلیوں سے گزر رہا ہے۔ سرمایہ کاری کو راغب کرنے، جدت طرازی کو فروغ دینے اور قومی سطح پر صحت کی سہولیات کے معیار کو بہتر بنانے میں اس صنعت کے کردار کو وسعت دینے کے لیے ایک شفاف، قابلِ پیش گوئی اور سادہ ضابطہ جاتی نظام ناگزیر ہے۔

اس تناظر میں، ہائی نون آپریشنل عمدگی، محتاط لاگت کے انتظام، مصنوعات کے پورٹ فولیو میں تنوع اور نئی منڈیوں میں توسیع کے ذریعے پائیدار ترقی اور منافع کے حصول پر توجہ مرکوز رکھے ہوئے ہے۔ کمپنی بدلتی ہوئی مارکیٹ کی صورتحال کے مطابق خود کو ڈھالنے، اپنی مسابقتی پوزیشن کو مزید مضبوط بنانے اور ترقی کے نئے مواقع سے فائدہ اٹھانے کا عمل جاری رکھے گی۔ اس کے ساتھ ساتھ، مالیاتی نظم و ضبط برقرار رکھنے اور اپنے حصص یافتگان سمیت دیگر متعلقہ فریقوں کے لیے قدر میں اضافے کے طویل مدتی عزم کو بھی برقرار رکھا جائے گا۔

ڈائریکٹرز رپورٹ

ہائی نون لیبارٹریز لمیٹڈ کے ڈائریکٹرز 30 ستمبر 2026 کو ختم ہونے والے نو ماہی کے لئے کمپنی اور گروپ کی رپورٹ بمعہ غیر آڈٹ شدہ مختصر عبوری مالیاتی گوشوارے پیش کرتے ہوئے خوشی محسوس کرتے ہیں۔

پاکستان کی معروف صحت کی مصنوعات بنانے والی کمپنیوں میں شامل ہونے کے ناتے، آپ کی کمپنی ادویات اور متعلقہ صحت کی مصنوعات کی تیاری، درآمد، فروخت اور مارکیٹنگ کے ذریعے زندگیوں اور مریضوں کی دیکھ بھال کو بہتر بنانے کے لیے پرعزم ہے۔

مالی جھلکیاں

سال 2025 کی اسی مدت کے مقابلے میں خالص فروخت میں 3.8٪ اضافہ ہوا۔ اس ترقی کی بنیادی وجوہات میں مصنوعات کے بہتر امتزاج، فروخت کے حجم میں اضافے اور قیمتوں کے بہتر حصول نے اہم کردار ادا کیا۔ اس کے علاوہ، مصنوعات کے پورٹ فولیو میں تنوع اور مارکیٹ میں کمپنی کی مضبوط پوزیشن نے بھی اس نمو کو تقویت دی۔ مجموعی منافع میں بھی اسی مدت کے دوران 5.1٪ اضافہ ہوا، جبکہ مجموعی منافع کا مارجن 55٪ سے بڑھ کر 56٪ ہو گیا۔

صنعت کو درپیش مسلسل مشکلات کے باوجود، کمپنی نے عملیاتی کارکردگی میں بہتری پر توجہ برقرار رکھی، قیمتوں سے متعلق ریگولیٹری ایڈجسٹمنٹس سے فائدہ اٹھایا اور لاگت کے دباؤ کو کم کرنے اور کاروباری کارکردگی کو برقرار رکھنے کے لیے مارکیٹ کی معلومات سے مؤثر استفادہ کیا۔ اس کے نتیجے میں، آپریٹنگ مارجن 21٪ سے بڑھ کر 22٪ ہو گیا، جو 100 بیسس پوائنٹ کے اضافے کو ظاہر کرتا ہے۔ تاہم، مؤثر ٹیکس کی شرح میں اضافے کے باعث ان فوائد کا اثر زائل ہو گیا، اور گزشتہ سال کی اسی مدت کے مقابلے میں ٹیکس کے بعد منافع تقریباً برقرار رہا۔

کمپنی توقعات سے بہتر کارکردگی کا مظاہرہ جاری رکھے ہوئے ہے اور اپنے اسٹریٹجک اہداف کے حصول کی جانب نمایاں پیش رفت کر رہی ہے۔

آپریٹنگ نتائج

زیرِ جائزہ 30 ستمبر 2026 کو ختم ہونے والے نو ماہی کے دوران کمپنی کی مالیاتی کارکردگی درج ذیل ہے:

	30 ستمبر 2026	30 ستمبر 2025
	روپے (000,000)	
فروخت	19,324	18,615
گراس منافع	10,764	10,240
گراس منافع فیصد	56%	55%
آپریٹنگ منافع	4,325	3,880
آپریٹنگ منافع فیصد	22%	21%
مالی لاگت	(65)	(91)
دیگر آمدنی	345	333
ٹیکس اور لیوی سے پہلے منافع	4,605	4,122
ٹیکس اور لیوی	(1,984)	(1493)
ٹیکس اور لیوی کے بعد منافع	2,621	2,628

Un-Consolidated Condensed Interim Financial Statements

Highnoon Laboratories Limited

For The Nine Months Ended September 30, 2026



Condensed Interim Un-Consolidated Statement of Financial Position As at 30 September 2026 (Un Audited)

	Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
		(Rupees)	
ASSETS			
NON CURRENT ASSETS			
Property, plant and equipment	9	4,045,198,087	3,719,579,406
Intangible assets		24,820,293	37,851,548
Long-term investment		325,000,000	325,000,000
Long-term deposits		135,459,689	81,588,597
Long-term loans and advances	10	499,417,707	437,821,751
		5,029,895,776	4,601,841,302
CURRENT ASSETS			
Inventories	11	5,270,250,205	5,088,463,951
Trade receivables	12	4,186,679,738	4,207,368,520
Advances, trade deposits and prepayments		623,257,931	625,622,547
Other receivables	13	383,039,292	224,606,241
Short-term investments	14	1,994,457,310	3,059,622,682
Tax refunds due from the Government		134,422,539	136,872,796
Cash and bank balances	15	842,994,828	468,796,488
		13,435,101,843	13,811,353,225
TOTAL ASSETS		18,464,997,619	18,413,194,527

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Financial Position As at 30 September 2026 (Un Audited)

	Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
		(Rupees)	
EQUITY AND LIABILITIES			
Share capital and reserves			
Authorized share capital			
100,000,000 (December 31, 2025: 100,000,000)			
Ordinary shares of Rs. 10 each		1,000,000,000	1,000,000,000
Issued, subscribed and paid up share capital	16	529,833,630	529,833,630
Capital reserves			
Surplus on revaluation of property, plant and equipment - net of tax		826,116,887	842,005,340
Revenue reserves		11,785,960,603	11,798,168,844
		13,141,911,120	13,170,007,814
Non current liabilities			
Lease liabilities		271,342,626	380,821,593
Long-term loan - secured	17	231,956,795	2,423,493
Deferred tax liabilities		171,470,045	204,351,890
Deferred liabilities		146,461,960	145,253,907
		821,231,426	732,850,883
Current liabilities			
Trade and other payables		3,112,039,533	2,983,181,105
Contract liabilities		37,722,343	227,677,836
Unclaimed dividend		413,325,468	304,559,821
Current portion of long-term liabilities		122,577,975	117,974,112
Taxation - net		816,189,754	876,942,956
		4,501,855,073	4,510,335,830
TOTAL EQUITY AND LIABILITIES		18,464,997,619	18,413,194,527
CONTINGENCIES AND COMMITMENTS	18		

The annexed notes from 1 to 30 form an integral part of these unconsolidated condensed interim financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Profit or Loss (Un Audited)

For The Nine Months Ended 30 September 2026

	Note	Nine Months Ended 30 September		Quarter ended 30 September	
		2026	2025	2026	2025
		----------(Rupees) ---------		----------(Rupees) ---------	
Revenue from contracts with customers- net	19	19,323,872,834	18,614,843,018	6,617,015,900	6,575,586,343
Cost of revenue	20	(8,560,263,501)	(8,375,143,514)	(2,933,035,101)	(2,857,168,006)
Gross profit		10,763,609,333	10,239,699,504	3,683,980,799	3,718,418,337
Distribution, selling and promotional expenses		(4,853,214,516)	(5,067,607,599)	(1,518,554,769)	(1,876,789,080)
Administrative and general expenses		(1,119,364,390)	(1,063,957,082)	(418,552,385)	(386,288,496)
Other operating expenses		(465,910,250)	(227,950,543)	(133,141,586)	(47,958,135)
		(6,438,489,156)	(6,359,515,224)	(2,070,248,740)	(2,311,035,711)
Profit from operations		4,325,120,177	3,880,184,280	1,613,732,059	1,407,382,626
Other income	21	345,046,550	332,611,911	138,615,249	102,982,389
Finance costs		(65,194,081)	(91,126,361)	(26,499,748)	(37,002,185)
Profit before income tax and levy		4,604,972,646	4,121,669,830	1,725,847,560	1,473,362,830
Levy		-	-	-	-
Profit before income tax		4,604,972,646	4,121,669,830	1,725,847,560	1,473,362,830
Taxation	22	(1,983,901,190)	(1,493,279,398)	(782,231,837)	(472,283,351)
Profit after tax for the period		2,621,071,456	2,628,390,432	943,615,723	1,001,079,479
Earnings per share - basic and diluted (Rupees)	23	49.47	49.61	17.81	18.89

The annexed notes from 1 to 30 form an integral part of these unconsolidated condensed interim financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Comprehensive Income (Un Audited)

For The Nine Months Ended 30 September 2026

	Nine Months Ended 30 September		Quarter ended 30 September	
	2026	2025	2026	2025
	------(Rupees) ------		------(Rupees) ------	
Profit after tax for the period	2,621,071,456	2,628,390,432	943,615,723	1,001,079,479
Other comprehensive income				
Items that will be reclassified subsequently to statement of profit or loss	-	-	-	-
Items that will not be reclassified subsequently to statement of profit or loss	-	-	-	-
Total comprehensive income for the period	2,621,071,456	2,628,390,432	943,615,723	1,001,079,479

The annexed notes from 1 to 30 form an integral part of these unconsolidated condensed interim financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Cash Flow (Un Audited)

For The Nine Months Ended 30 September 2026

	Note	Nine Months Ended 30 September 2026	2025
		----------(Rupees) ----------	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	24	4,775,681,229	2,458,566,403
Income taxes paid		(2,077,536,237)	(935,348,055)
Workers' Profit Participation Fund paid		(7,828,611)	-
Workers' Welfare Fund paid		(84,067,033)	(81,798,187)
Central Research Fund paid		(71,565,722)	-
Gratuity paid		(17,700,134)	(616,901,796)
Finance cost paid		(44,712,106)	(91,126,361)
		(2,303,409,843)	(1,725,174,399)
Net cash generated from operating activities	A	2,472,271,386	733,392,004
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(724,907,215)	(664,316,596)
Purchase of intangible assets		-	(10,207,638)
Increase in long-term investment		-	(125,000,000)
(Increase) / decrease in long term advances		17,570,711	15,978,631
Loan to subsidiary - net		(175,000,000)	(125,000,000)
Short term investments - net		1,082,594,572	2,270,524,235
Long term deposits - net		(53,871,092)	(19,297,468)
Dividend income on short term investments		13,102,694	10,676,633
Proceeds from disposal of property plant and equipment		145,345,158	267,285,333
Net cash (used in) / generated from investing activities	B	304,834,828	1,620,643,130
CASH FLOWS FROM FINANCING ACTIVITIES			
Repayment of lease liabilities - net		(120,559,741)	180,601,292
Long term loan - net		258,054,370	(440,422,222)
Dividend paid		(2,540,402,503)	(2,024,851,217)
Net cash used in financing activities	C	(2,402,907,874)	(2,284,672,147)
Net (decrease)/ increase in cash and cash equivalents	(A+B+C)	374,198,340	69,362,988
Cash and cash equivalents at beginning of the period		468,796,488	709,206,965
Cash and cash equivalents at end of the period		842,994,828	778,569,953

The annexed notes from 1 to 30 form an integral part of these unconsolidated condensed interim financial statements.

Dr. Adeel Abbas Haideri	Taufiq Ahmed Khan	Ashfaq Alidina
Chief Executive Officer	Director	Chief Financial Officer

Condensed Interim Un-Consolidated Statement of Changes in Equity (Un Audited)

For The Nine Months Ended September 30, 2026

	Issued, subscribed and paid-up capital	Capital Reserves	Revenue reserves			Total
		Revaluation Surplus on operating fixed assets	General reserve	Accumulated profit	Sub total	
	---------- Rupees ----------					
Balance as at January 01, 2025 - (audited)	529,833,630	865,425,008	114,000,000	9,711,907,063	9,825,907,063	11,221,165,701
Transaction with owners, recorded directly in equity						
Final dividend @ Rs. 40 per share for the year ended December 31, 2024	-	-	-	(2,119,334,520)	(2,119,334,520)	(2,119,334,520)
Total comprehensive income for the nine months ended September 30, 2025						
Profit for the period	-	-	-	2,628,390,432	2,628,390,432	2,628,390,432
Other comprehensive income for the period	-	-	-	-	-	-
	-	-	-	2,628,390,432	2,628,390,432	2,628,390,432
Surplus transferred to accumulated profit						
Incremental depreciation relating to surplus on revaluation - net of tax	-	(17,564,751)	-	17,564,751	17,564,751	-
Balance as at September 30, 2025 - (un-audited)	529,833,630	847,860,257	114,000,000	10,238,527,726	10,352,527,726	11,730,221,613
Balance as at January 01, 2026 - (audited)	529,833,630	842,005,340	114,000,000	11,684,168,844	11,798,168,844	13,170,007,814
Transaction with owners, recorded directly in equity						
Final dividend @ Rs. 50 per share for the year ended December 31, 2025	-	-	-	(2,649,168,150)	(2,649,168,150)	(2,649,168,150)
Total comprehensive income for the nine months ended September 30, 2026						
Profit for the period	-	-	-	2,621,071,456	2,621,071,456	2,621,071,456
Other comprehensive income for the period	-	-	-	-	-	-
	-	-	-	2,621,071,456	2,621,071,456	2,621,071,456
Surplus transferred to accumulated profit						
Incremental depreciation relating to surplus on revaluation - net of tax	-	(15,888,453)	-	15,888,453	15,888,453	-
Balance as at September 30, 2026 - (un-audited)	529,833,630	826,116,887	114,000,000	11,671,960,603	11,785,960,603	13,141,911,120

The annexed notes from 1 to 30 form an integral part of these unconsolidated condensed interim financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

1 LEGAL STATUS AND NATURE OF BUSINESS

Highnoon Laboratories Limited ("the Company") was incorporated in Pakistan under the repealed Companies Ordinance 1984 (now Companies Act, 2017) ("the Act") and its shares are quoted on Pakistan Stock Exchange (PSX) since November 1994. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and related consumer products.

2 GEOGRAPHICAL LOCATION AND ADDRESSES OF BUSINESS UNITS

The registered office of the Company is situated at 17.5 km, Multan Road, Lahore.

The geographical locations and addresses of the Company's business units including production facilities are as under:

Business Units	Geographical Location	Address
Manufacturing facility	Lahore	17.5 KM, Multan Road, Lahore.
Corporate office	Lahore	Office No. 901, Tricon Corporate Centre, Jail Road, Lahore.
Sales office	Karachi	202 Anam Empire, Block 7/8 KCHS, Shahrah-e-Faisal, Karachi.
Sales office	Lahore	14-G, Block L, Gulberg - III, Lahore.

3 BASIS OF PREPARATION

3.1 Statement of compliance

These unconsolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. These accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34 - Interim Financial Reporting, issued by the International Accounting Standard Board (IASB) as notified under the Companies Act, 2017;
- Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan as notified under the Companies Act , 2017; and
- Provisions of, directives and notifications issued under the Companies Act, 2017.

Where provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

These unconsolidated condensed interim financial statements are un-audited and are being submitted to the shareholders as required under section 237 of the Companies Act, 2017 and the listing regulations of the Pakistan Stock Exchange.

These unconsolidated condensed interim financial statements do not include all the information and disclosures required for full annual financial statements and should be read in conjunction with the annual financial statements of the Company as at and for the year ended December 31, 2025 which have been prepared in accordance with approved accounting standards as applicable in Pakistan. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the last annual financial statements.

The comparative statement of financial position presented in these unconsolidated condensed interim financial statements have been extracted from the annual audited financial statements of the Company for the year ended December 31, 2025, whereas the comparative unconsolidated condensed interim statement of profit or loss, unconsolidated condensed interim statement of comprehensive income, unconsolidated condensed interim statement of cash flows and unconsolidated condensed interim statement of changes in equity are extracted from the unaudited unconsolidated condensed interim financial statements for the nine months ended September 30, 2025.

3.2 Basis of measurement

The unconsolidated condensed interim financial statements have been prepared under the historical cost convention, except for certain classes of operating fixed assets (as mentioned in unconsolidated financial statements of the Company for the year ended December 31, 2025) and certain employees' retirement benefits which are measured at revalued amounts and present value, respectively.

3.3 Separate financial statements

These unconsolidated condensed interim financial statements are the separate financial statements of the Company in which investment in the subsidiary is accounted for on the basis of cost less accumulated impairment losses, if any; consolidated financial statements are presented separately.

The Company has following investment:

Company name	Country of incorporation	Percentage of shareholding	Nature of business
The Subsidiary Curexa Health (Private) Limited	Pakistan	100%	The principal object is to carry out business as manufacturer and dealer of all kinds of pharmaceuticals.

3.4 Functional and presentation currency

These unconsolidated condensed interim financial statements are presented in Pakistani Rupee ("Rs"), which is also the functional currency of the Company.

4 APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS TO PUBLISHED APPROVED ACCOUNTING AND REPORTING STANDARDS

4.1 Amendments to published accounting and reporting standards which became effective during the period:

Certain standards, amendments and interpretations to approved accounting standards are effective for accounting periods beginning on January 01, 2026, but are considered not to be relevant or to have any significant effect on the Company's operations (although they may affect the accounting for future transactions and events) and are, therefore, not detailed in these unconsolidated condensed interim financial statements.

4.2 Standards, amendments and interpretations to existing standards that are not yet effective and have not been early adopted by the Company:

There are certain standards, amendments to the accounting standards and interpretations that are mandatory for the Company's accounting periods beginning on or after January 1, 2026, but are considered not to be relevant or expected to have any significant effect on the Company's operations except as follows:

IFRS 18 Presentation and Disclosure in Financial Statements, which was issued by the IASB in April 2024 supersedes IAS 1 and will result in major consequential amendments to IFRS Accounting Standards including IAS 8 Basis of Preparation of Financial Statements (renamed from Accounting Policies, Changes in Accounting Estimates and Errors). Even though IFRS 18 will not have any effect on the recognition and measurement of items in the financial statements, it is expected to have a significant effect on the presentation and disclosure of certain items. These changes include categorisation and sub-totals in the statement of profit or loss, aggregation/disaggregation and labelling of information, and disclosure of management-defined performance measures.

5 MATERIAL ACCOUNTING POLICIES INFORMATION

The accounting policies adopted in the preparation of these unconsolidated condensed interim financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended December 31, 2025 execpt otherwise stated in these unconsolidated condensed interim financial statements.

6 TAXATION AND OTHERS

6.1 The provisions for taxation for the nine months and quarter ended September 30, 2026, have been made using the estimated effective tax rate applicable to expected total annual earnings. The applicable income tax rate for the Tax Year 2026 is 29% plus super tax. Income tax expense is recognized in each interim period based on best estimate of the weighted average annual income tax rate expected for the full financial year.

Amounts accrued for income tax expense in one interim period may have to be adjusted in a subsequent interim period of that financial year if the estimate of the annual income tax rate changes.

6.2 Provisions in respect of Workers' Welfare Fund and Workers' Profit Participation Fund are estimated based on management judgment and prevailing laws; these are subject to final adjustments in the annual audited financial statements.

7 USE OF ESTIMATES AND JUDGEMENTS

The preparation of these unconsolidated condensed interim financial statements, in conformity with accounting and reporting standards as applicable in Pakistan requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Actual results may differ from the estimates. During the preparation of these unconsolidated condensed interim financial statements, the significant judgements made by management in applying the Company's accounting policies and the key sources of estimation and assumptions are consistent with those that were applied to the audited financial statements of the Company for the year ended December 31, 2025.

8 FINANCIAL RISK MANAGEMENT

The Company's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, interest rate risk and price risk), credit risk and liquidity risk.

There have been no significant changes in the risk management policies since the year end.

The unconsolidated condensed interim financial statements does not include all financial risk management information and disclosures required in the annual financial statements and should be read in conjunction with the Company's audited annual financial statements for the year ended December 31, 2025.

The Company's financial risk management objective and policies are consistent with that disclosed in the annual financial statements for the year ended December 31, 2025.

		Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			(Rupees)	
9	PROPERTY, PLANT AND EQUIPMENT			
	Operating fixed assets	9.1	3,123,195,927	2,883,497,808
	Right of use assets	9.2	451,917,289	557,996,242
			3,575,113,216	3,441,494,050
	Capital work-in-progress	9.3	470,084,871	278,085,356
			4,045,198,087	3,719,579,406
9.1	Owned assets			
	Opening book value		2,883,497,808	3,080,711,613
	Additions during the period / year	9.1.1	532,907,700	170,918,030
			3,416,405,508	3,251,629,643
	Disposals during the period / year	9.1.2	(96,632,991)	(88,479,462)
	Depreciation for the period / year		(196,576,590)	(279,652,373)
			(293,209,581)	(368,131,835)
	Closing book value		3,123,195,927	2,883,497,808
9.1.1	Additions during the period / year - cost			
	Building on freehold land		98,674,372	7,644,068
	Leasehold improvement		-	45,895,314
	Plant and machinery		296,250,497	61,247,172
	Laboratory equipment		48,696,951	18,776,979
	Furniture and fixture		3,499,660	996,510
	Electric and gas appliances		5,973,458	1,030,000
	IT and office equipment		27,481,424	27,023,411
	Vehicles		52,331,338	8,304,576
			532,907,700	170,918,030
9.1.2	Disposals during the period / year			
	Laboratory equipment		-	140,298
	IT and office equipment		3,955,581	1,553,533
	Furniture & Fixtures		30,793	-
	Vehicles		92,646,617	86,785,631
			96,632,991	88,479,462

		Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			(Rupees)	
9.2	Right of use assets			
	Opening book value		557,996,242	89,084,423
	Additions / transfer during the period / year - cost		-	590,509,302
			557,996,242	679,593,725
	Disposal / transferred to owned assets		(40,521,933)	(43,161,656)
	Depreciation for the period / year		(65,557,020)	(78,435,827)
			(106,078,953)	(121,597,483)
	Closing book value		451,917,289	557,996,242
9.3	Capital work-in-progress			
	Opening balance		278,085,356	177,078,595
	Addition during the period / year - cost		691,286,869	635,276,026
	Transfer during the period / year - cost		(499,287,354)	(534,269,265)
	Closing balance		470,084,871	278,085,356
10	LONG-TERM LOANS AND ADVANCES			
	Secured - considered good			
	Loan to employees - secured	10.1	45,734,422	57,841,093
	Less: current portion		(12,983,382)	(7,519,342)
			32,751,040	50,321,751
	Unsecured - considered good			
	Loan to subsidiary	10.2 & 10.3	600,000,000	425,000,000
	Less: Current maturity		(133,333,333)	(37,500,000)
			466,666,667	387,500,000
			499,417,707	437,821,751

10.1 These represent loan given to employees against the purchase of vehicles as per the Company's policy. These loans are for maximum period of 5 years. These loans are secured against the final settlement amount of employees. The loans carry an effective interest rate of 0% (2025: 0%) per annum and are repayable in cash in accordance with predefined repayment schedule. The impact of discounting to present value is assessed to be immaterial by the management.

10.2 This represents loan given to the Subsidiary at a markup of 3 Months KIBOR + 0.1% per annum. The loan is for a period of 4 years including grace period of one year and is repayable in 10 equal quarterly installments starting from May 2026.

10.3 This represents loan given to the Subsidiary at a markup of 3 Months KIBOR + 0.5% per annum. The loan is for a period of 4 years including grace period of one year and is repayable in 12 equal quarterly installments starting from March 2027.

	Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
		------(Rupees) -----	
11 INVENTORIES			
Raw materials			
In hand		2,528,285,847	2,771,431,365
In transit		413,621,853	449,765,074
With third party		203,440,345	135,911,573
		3,145,348,045	3,357,108,012
Packing material			
In hand		921,015,537	700,639,386
With third party		20,297,276	25,046,346
		941,312,813	725,685,732
Stores, spare parts and loose tools		190,793,945	163,223,850
Work in progress		400,172,318	502,840,820
Finished goods			
Trading - in hand		258,673,509	108,189,203
Manufactured		487,810,828	430,855,218
		746,484,337	539,044,421
Provision for slow moving and obsolete items	11.1	(153,861,253)	(199,438,884)
		5,270,250,205	5,088,463,951

11.1 Provision for slow moving and obsolete tems:			
Opening balance		199,438,884	194,124,310
Charge for the period / year	11.1.1	88,250,922	89,307,854
Write-off for the period / year		(133,828,553)	(83,993,280)
Closing provision		153,861,253	199,438,884

11.1.1 The Company has revised its accounting estimate relating to the provision for slow-moving raw materials. Effective during the current period, the provision rate for raw materials with a remaining shelf life of six months has been reduced from 100% to 50%, based on prevailing industry practice and management's assessment of the expected utilization of such materials.

Had there been no change in the accounting estimate, the provision for slow-moving raw materials for the current period would have been higher by Rs. 29.660 million.

			September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			----------(Rupees) ----------	
12	TRADE RECEIVABLES			
	Unsecured			
	Export sales		211,281,933	165,891,286
	Local sales	12.1	4,133,916,139	4,109,586,132
			4,345,198,072	4,275,477,418
	Less: allowance for expected credit losses	12.3	(158,518,334)	(68,108,898)
			4,186,679,738	4,207,368,520
12.1	Trade receivables include the following amounts due from the following related parties:			
	Curexa Health (Private) Limited		356,728,214	101,544,385
12.2	The aging of receivable from related parties at the reporting date is as follows:			
	Past due but not impaired		356,728,214	101,544,385
	Aging:			
	1-30 days		308,221,759	101,544,385
	31-60 days		48,506,455	-
			356,728,214	101,544,385
12.3	Allowance for expected credit losses:			
	Opening balance		68,108,898	57,645,999
	Charge during the year	12.3.1	90,409,436	10,462,899
			158,518,334	68,108,898

12.3.1 This includes expected credit loss amounting to Rs. 5.849 million in respect of Curexa Health (Private) Limited, a Subsidiary Company.

13	OTHER RECEIVABLES			
	Considered good			
	The Subsidiary - unsecured	13.1	20,825,657	29,675,707
	Current portion of long-term loan to the Subsidiary	10.2	133,333,333	37,500,000
			154,158,990	67,175,707
	Interest accrued		38,547,133	4,729,050
	Sales tax recoverable		190,333,169	152,561,484
	Others		-	140,000
			383,039,292	224,606,241

13.1 This represents receivable from Subsidiary against expenses incurred by the Company on behalf of Subsidiary amounting to Rs. 20.826 million (2025: Rs. 29.676 million). Interest has been charged on the outstanding receivable at a markup of 3 Months KIBOR + 0.5% per annum.

13.2 The aging of receivable from related parties at the reporting date is as follows:

	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
	------(Rupees) -----	
Past due but not impaired	20,825,657	29,675,707
Aging:		
1-30 days	7,863,811	29,675,707
31-60 days	12,961,846	-
61-90 days	-	-
Above 90 days	-	-
	20,825,657	29,675,707

14 SHORT-TERM INVESTMENTS

Investments at fair value through profit or loss			
Mutual funds - fair value through profit and loss	14.1	850,807,844	2,659,250,468
Term deposit receipts - at amortization cost	14.2	1,143,649,466	400,372,214
		1,994,457,310	3,059,622,682

14.1 These investments are measured at fair value through profit or loss:

Balance at the beginning of the period / year	2,659,250,468	3,471,920,933
Additions during the period / year	2,370,000,000	6,133,140,049
Redemption during the period / year	(4,351,818,294)	(7,290,579,760)
Realized gain on redemption of investment during the period / year	155,946,470	168,760,287
Un-realized (loss) / gain on remeasurement of investments during the period / year	17,429,200	176,008,959
Closing fair value of short-term investments	850,807,844	2,659,250,468

14.2 These represent investments in term deposit receipts. They carry average profit at the rate of ranging from 9.02% to 11.25% per annum (2025: 9.02% to 16% per annum) with maturity up to November 2026.

		Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			--------(Rupees) --------	
15	CASH AND BANK BALANCES			
	Cash in hand		250,200	100,000
	Balance with banks			
	Current accounts			
	- Local currency		221,613,998	201,119,358
	- Foreign currency		243,701,597	228,704,609
	Savings accounts		377,429,033	38,872,521
		15.1	842,744,628	468,696,488
			842,994,828	468,796,488

15.1 These represents savings accounts which carries average profit at the rate of ranging from 6.46% to 9.10% per annum (2025: 6.46% to 9.10% per annum).

		September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
		--------(Rupees) --------	
16	ISSUED, SUBSCRIBED AND PAID UP SHARE CAPITAL		
	5,905,000 (December 31, 2025: 5,905,000) ordinary shares of Rs. 10 each fully paid in cash	59,050,000	59,050,000
	95,000 (December 31, 2025: 95,000) ordinary shares of Rs.10 each issued for consideration other than cash	950,000	950,000
	46,983,363 (December 31, 2025: 46,983,363) ordinary shares of Rs. 10 each issued as bonus shares	469,833,630	469,833,630
		529,833,630	529,833,630

16.1 There is no shareholder agreement for voting rights, board selection, rights of first refusal and block voting.

16.2 Pharmatec Investments Limited and Route 2 health (Private) Limited hold 8.34% and 0.45%, respectively, of the ordinary shares of the Company.

		Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			--------(Rupees) --------	
17	LONG-TERM LOAN - SECURED			
	Long-term loan		245,983,251	6,319,789
	Less: Current portion shown under current liabilities		(14,026,456)	(3,896,296)
			231,956,795	2,423,493
17.1	The movement of long-term loan is as follows:			
	Opening balance as at January 01,	17.1.1	6,319,789	447,716,085
	Loan obtained during the period / year	17.1.2	242,585,684	-
	Principal payments made during the period / year		(2,922,222)	(441,396,296)
			245,983,251	6,319,789
	Current portion shown under current liabilities		(14,026,456)	(3,896,296)
	Closing balance		231,956,795	2,423,493

17.1.1 This includes loan obtained from MCB Bank Limited with maturity date of June 10, 2029 under facility for setting up solar based power project under SBP financing scheme for renewable energy having sanctioned limit of Rs. 50 million (2025: Rs. 50 million) and carries markup at the rate of 2% + 0.5% per annum payable quarterly (2025: 2% + 0.5%) whereas principal is repayable in 27 equal quarterly instalments starting from December 10, 2022. This facility is secured against lien on mutual funds up to Rs. 67 million placed in MCB Investment Management Limited. The loan has been measured at its fair value in accordance with IFRS 9 (Financial Instruments) using effective interest rate of 3 months KIBOR at respective draw down date.

17.1.2 The Company has obtained long-term Shariah-compliant term financing facility from Meezan Bank Limited with total limits of PKR 500 million for capital expenditure and BMR requirements. The facilities comprise SBP LTFF and commercial terms, carry markup ranging from SBP Base Rate - 3.00% per annum (with a 5% floor and 35% cap), a 5-year tenure including a 1-year grace period and eight equal semi-annual repayments. The facilities are secured by a 1st Pari Passu charge on all present and future plant and machinery of the Company with a 25% margin.

17.2 The difference between fair value of loan and loan proceeds has been recognised as deferred grant as per requirements of IAS 20 (Accounting for Government grants and disclosure of Government assistance) and as per circular 11/2020 issued by the Institute of Chartered Accountants of Pakistan.

18 CONTINGENCIES AND COMMITMENTS

18.1 Contingencies

There have been no significant changes in contingencies as reported in the annual audited unconsolidated financial statements of the Company for the year ended December 31, 2025 except following:

18.1.1 The Assistant / Deputy Commissioner Inland Revenue has issued an order under sections 205 read with 137(1) of the Income Tax Ordinance, 2001, in respect of Tax Year 2023, creating a demand of Rs. 56.05 million on account of default surcharge due to failure of full discharge of liability of super tax.

Being aggrieved by the said order, the Company has preferred an appeal before the Commissioner Inland Revenue (Appeals) [CIR (A)], which is pending adjudication. No provision has been recognized by the Company, as the management, based on the opinion of its tax consultants, expects a favorable outcome.

18.1.2 In respect of the contingency reported under note 30.1.8 to the audited financial statement for the year ended December 31, 2025, the Civil Originals relating to, inter alia, the related party transactions have been clubbed with the Company's Writ Petition seeking a stay of the proceedings initiated by the SECP and are presently fixed for hearing before the Lahore High Court.

In the matter concerning the rectification of shares, the Lahore High Court dismissed the petition on grounds of limitation. The plaintiffs subsequently filed a Civil Petition for Leave to Appeal (CPLA) before the Supreme Court. Thereafter, vide its order dated April 22, 2026, a regular bench of the Supreme Court remanded the matter to Lahore High Court for reconsideration along with multiple other petitions pertaining to the same issue. The Company has since then also filed a revision petition before the Supreme Court of Pakistan. The management, based on the assessment of its concerned legal advisors, is of the view that no outflow of economic resources is expected to occur based on the aforementioned petition.

The Company is actively pursuing the above matters at respective forums. Based on the advice of the legal counsel, the Company is hopeful for the favorable outcome of the matters. Hence, no provision has been made in these financial statements.

		Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			--------(Rupees) --------	
18.2	Commitments			
	The Company has commitments against:			
	Letter of credit		947,565,818	881,124,006
	Bank contracts		295,991,244	489,730,620
	Ijarah rentals	18.2.1	726,123,030	322,126,814
	Capital work in progress		71,526,985	80,240,684
			2,041,207,077	1,773,222,124
18.2.1	Future payments under Ijarah			
	Within one year		206,041,524	80,627,044
	After one year but not more than five years		520,081,506	241,499,770
			726,123,030	322,126,814

19 REVENUE FROM CONTRACTS WITH CUSTOMERS- NET

19.1 Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contracts with customers :

	Un-audited			
	Nine Months Period Ended 30 September		Quarter ended 30 September	
	2026	2025	2026	2025
	---------- (Rupees) ----------			
Manufacturing:				
Local	22,581,127,701	18,891,576,073	8,582,121,704	6,562,163,667
Export	662,669,595	1,531,682,021	295,174,582	676,015,467
	23,243,797,296	20,423,258,094	8,877,296,286	7,238,179,134
Trading	1,374,037,111	1,103,465,531	418,486,916	325,958,947
Toll manufacturing	653,894,469	614,707,380	273,002,786	243,504,514
Less:				
Sales tax	(189,973,606)	(179,894,168)	(60,726,024)	(52,133,540)
Trade discount	(3,741,624,646)	(2,845,522,080)	(1,874,052,811)	(943,571,649)
Sales return	(2,016,257,790)	(501,171,739)	(1,016,991,253)	(236,351,063)
	19,323,872,834	18,614,843,018	6,617,015,900	6,575,586,343

		Un-audited Nine Months Ended 30 September 2026	2025
		----------(Rupees) ---------	
19.2	Geographical information		
	Pakistan	18,739,631,423	17,083,728,249
	Afghanistan	-	1,138,469,885
	Azerbaijan	5,523,310	-
	Cambodia	9,427,123	18,883,757
	France	134,667,118	69,098,734
	Iraq	114,324,841	116,763,815
	Kenya	54,753,725	37,024,249
	Mauritius	7,152,320	2,121,816
	Myanmar	2,314,743	-
	Sierra Leone	610,060	-
	Somalia	63,425,906	46,978,525
	Sri Lanka	90,759,212	70,701,337
	Sudan	70,584,223	11,495,219
	Tanzania	6,438,921	-
	Turkmenistan	19,655,584	14,260,472
	Zambia	4,604,325	5,316,960
		19,323,872,834	18,614,843,018

		Un-audited			
		Nine Months Period Ended 30 September		Quarter ended 30 September	
		2026	2025	2026	2025
		---------- (Rupees) ----------			
20	COST OF REVENUE				
	Opening stock of finished goods	539,044,421	743,231,873	786,670,170	715,614,475
	Cost of goods manufactured	7,949,777,005	7,260,403,818	2,679,298,000	2,286,377,015
	Purchased finish products	817,926,412	841,042,708	213,551,268	324,711,401
	Available stock for sale	9,306,747,838	8,844,678,399	3,679,519,438	3,326,702,891
	Closing stock of finished goods	(746,484,337)	(469,534,885)	(746,484,337)	(469,534,885)
	Cost of revenue	8,560,263,501	8,375,143,514	2,933,035,101	2,857,168,006

		Note	Un-audited Nine Months Ended 30 June 2026	2025
			----------(Rupees) ---------	
21	OTHER INCOME			
	Return on deposits and mark-up on interest bearing accounts		66,802,461	27,698,602
	Dividend income on short term investment		13,102,694	10,676,633
	Unrealized gain on re-measurement of short term investment to fair value		17,429,200	159,441,960
	Realized gain on short term investment		155,112,586	84,043,829
	Exchange gain - net		4,621,426	2,066,989
	Interest on loan to subsidiary		51,852,168	3,997,055
	Interest on other receivable		2,995,129	-
	Royalty income from subsidiary	21.1	10,294,493	2,399,678
	Royalty income from associate	21.1	4,333,383	5,662,200
	Deferred income		2,602,914	-
	Gain on disposal of operating fixed asset		8,190,234	35,502,805
	Scrap sales		250,133	299,540
	Rental income	21.2	6,231,417	-
	Others		1,228,312	822,620
			345,046,550	332,611,911

21.1 This represents royalty income from Curexa Health (Private) Limited and Route 2 Health (Private) Limited, at the rates of 0.5% and 2.5% of net sales, respectively.

21.2 This represents rental income charged to the Subsidiary Company in respect of vehicles provided.

		Note	Un-audited Nine Months Ended 30 September 2026	2025
			----------(Rupees) ---------	
22	TAXATION			
	Current tax			
	-current period		1,846,422,381	1,493,279,398
	-prior period	22.1 & 22.2	170,360,654	-
			2,016,783,035	1,493,279,398
	Deferred tax		(32,881,845)	-
			1,983,901,190	1,493,279,398

22.1 This includes tax payments amounting to Rs. 16.896 million made against demands raised for Tax Years 2019, 2021, and 2022.

22.2 On January 27, 2026, Federal Constitutional Court upheld the legality of the Super Tax under Sections 4B and 4C of the Income Tax Ordinance 2001, ruling it constitutional and enforceable. Pursuant to passing of the order company has recognized super tax provision amounting to Rs. 153.464 million for financial year 2022 and 2023.

		Un-audited			
		Nine Months Ended 30 September		Quarter ended 30 September	
		2026	2025	2026	2025
		---------- (Rupees) ----------			
23	EARNINGS PER SHARE				
	Profit for the period - (Rupees)	2,621,071,456	2,628,390,432	943,615,723	1,001,079,479
	Weighted average number of ordinary shares	52,983,363	52,983,363	52,983,363	52,983,363
	Basic and diluted - (Rupees)	49.47	49.61	17.81	18.89

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

		Note	(Un-audited) Nine Months Ended 30 September 2026	2025
			----------(Rupees)--- ------	
24	CASH FLOWS FROM OPERATING ACTIVITIES			
	Profit before income tax and levy		4,604,972,646	4,121,669,830
	Adjustments for non-cash and other items:			
	Depreciation of operating fixed assets		262,133,610	227,646,444
	Amortization of intangible assets		13,031,256	11,290,984
	Provision for defined benefit obligation	8.1	6,071,755	376,528,691
	Provision for slow moving and obsolete stocks		(45,577,631)	7,685,497
	Provision for Workers' Profit Participation Fund		250,270,253	216,175,371
	Provision for Workers Welfare Fund	10	100,108,101	81,643,395
	Provision for Central Research Fund		50,054,051	35,791,962
	Finance cost		65,194,081	91,126,361
	Exchange gain - net		(4,621,426)	(2,066,989)
	Gain on disposal of property plant and equipment	21	(8,190,234)	(35,502,805)
	Un-realized gain on remeasurement of investments	21	(17,429,200)	-
	Dividend income on short term investment	21	(13,102,694)	(10,676,633)
	Allowance for expected credit loss		90,409,436	-
			748,351,358	999,642,278
	Cash flow before working capital changes		5,353,324,004	5,121,312,107
	Working capital changes:			
	(Increase) / decrease in current assets:			
	Stock in trade		(136,208,623)	(1,309,421,030)
	Trade debts		(65,099,228)	(1,563,706,950)
	Advances, trade deposits and prepayments		2,364,616	(453,858,998)
	Other receivables		(62,599,718)	(4,845,209)
	Tax refunds due from the Government		2,450,257	(80,052,086)
	Increase / (decrease) in current liabilities:			
	Trade and other payables		(128,594,586)	681,463,862
	Contract liabilities		(189,955,493)	67,674,706
			(577,642,775)	(2,662,745,704)
	Cash generated from operations		4,775,681,229	2,458,566,403

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

25 BALANCES AND TRANSACTIONS WITH RELATED PARTIES

The related parties of the Company comprise subsidiary, associated companies, companies in which directors are interested, staff retirement funds and directors and key management personnel. The transactions with related parties are carried out under the related party transactions policy approved by the Board of Directors of the Company. Details of transactions with related parties and balances with them at period end, other than those which have been disclosed elsewhere in these financial statements, are as follows:

25.1 Transactions during the period:

Name of related party	Relationship	Nature of transaction	(Un-audited) Nine Months Ended 30 September 2026	2025
			-------Rupees)-------	
Curexa Health (Private) Limited	Subsidiary (100% owned subsidiary)	Sales during the period	1,129,879,372	470,998,179
		Purchases	811,588	119,654,732
		Royalty income	10,294,493	2,399,678
		Interest on loan to subsidiary	51,852,168	3,997,055
		Interest on other receivable	2,995,129	-
		Interest repayment	53,035,072	-
		Payments made by Company on behalf of the Subsidiary	54,929,062	-
		Receipts during the period	951,764,276	324,426,976
		Payments during the period	129,808,816	-
		Loan to subsidiary	200,000,000	125,000,000
		Loan repayment by subsidiary	25,000,000	-
Route 2 health (Private) Limited	Associate (Common directorship and shareholder of 0.45% (2025:0.45%)	Sales during the period - net	-	115,296,184
		Royalty income	4,333,383	5,662,200
		Receipts during the period	4,333,383	127,201,616
		Dividend paid	11,903,950	9,523,160

Name of related party	Relationship	Nature of transaction	(Un-audited) Nine Months Ended 30 September 2026	2025
			-------Rupees)-------	
Pharmatec Investments Limited	Associate Common control and sharehold er of 8.34% (2025:8.34%)	Dividend paid	220,812,100	176,649,680
Highnoon Laboratories Limited	Staff retirement funds	Contribution to provident fund	161,454,248	133,143,258
Staff Provident Fund		Dividend paid	10,677,500	8,542,000
Highnoon Laboratories Limited	Staff welfare trust	Contribution to staff welfare trust	6,278,235	5,454,072
Staff Welfare Trust		Dividend paid	6,148,250	7,860,680

25.2 Balance outstanding as at reporting date:

Name of related party	Relationship	Nature of transaction	Un Audited 30 September 2026	Audited 31 December 2025
			--------(Rupees) --------	
Curexa Health (Private) Limited	Subsidiary (100% owned subsidiary)	Trade receivables	356,728,214	101,544,385
		Other receivables	20,825,657	29,675,707
		Accrued markup	-	1,182,903
		Trade and other payables	-	128,997,228
		Loan receivable	600,000,000	425,000,000
Highnoon Laboratories Limited Staff Provident Fund	Staff retirement funds	Payable to provident fund	25,904,541	16,903,336
Highnoon Laboratories Limited Staff Welfare Trust	Staff welfare trust	Payable to staff welfare trust	1,791,667	1,030,236

25.3 No cost has been charged by the Company to Curexa Health (Private) Limited (a wholly owned subsidiary) for use of SAP and its maintenance services provided during the period.

25.4 Transactions with key management personnel under the terms of employment are excluded from related party transactions.

Notes to the Condensed Interim Un-Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

26 EVENTS AFTER THE REPORTING DATE

These are no significant reportable event after the unconsoldiated condensed interim statement of financial position.

27 CORRESPONDING FIGURES

27.1 Corresponding figures have been re-arranged or reclassified wherever necessary, for better and fair presentation. However no significant rearrangement / reclassification has been made during the period.

27.2 In order to comply with the requirements of International Accounting Standard 34 - 'Interim Financial Reporting', corresponding figures in the unconsolidated condensed interim statement of financial position comprise of balances as per the audited annual financial statements of the Company for year ended December 31, 2025 and the corresponding figures in the unconsolidated condensed interim statement of profit or loss and the unconsolidated condensed interim comprehensive income, unconsolidated condensed interim statement of cash flows and unconsolidated condensed interim statement of changes in equity comprise of balances of comparable period as per the unconsolidated condensed interim financial statements of the Company for the nine months ended September 30, 2025.

28 SEGMENT REPORTING

The chief operating decision maker (i.e. the Board of Directors) considers the whole business as one operating segment.

29 DATE OF AUTHORIZATION OF ISSUE

The Board of Directors of the Company authorized these unconsolidated financial statements for issuance on October 27, 2026.

30 GENERAL

The figures in these unconsolidated financial statements are rounded off to the nearest rupee, unless otherwise stated.

Dr. Adeel Abbas Haideri	Taufiq Ahmed Khan	Ashfaq Alidina
Chief Executive Officer	Director	Chief Financial Officer

Consolidated Condensed Interim Financial Statements

Highnoon Laboratories Limited

For The Nine Months Ended September 30, 2026



Condensed Interim Consolidated Statement of Financial Position As at 30 September 2026 (Un Audited)

	Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
		(Rupees)	
ASSETS			
Non-current assets			
Property, plant and equipment	9	4,860,330,451	4,400,566,790
Intangible assets		24,820,293	37,851,548
Goodwill		834,230	834,230
Long-term deposits		163,171,115	84,586,147
Long-term loans and advances	10	45,721,946	54,421,386
		5,094,878,035	4,578,260,101
Current assets			
Inventories	11	5,836,615,925	5,713,841,339
Trade receivables	12	4,464,999,393	4,400,848,568
Advances, trade deposits and prepayments		717,618,516	657,630,072
Other receivables		246,168,181	176,743,922
Short term investments	13	1,994,457,310	3,059,622,682
Tax refunds due from the Government		357,827,836	265,482,460
Cash and bank balances	14	1,045,717,570	584,225,906
		14,663,404,731	14,858,394,949
TOTAL ASSETS		19,758,282,766	19,436,655,050

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Financial Position As at 30 September 2026 (Un Audited)

	Note	Un Audited 30 September 2026	Audited 31 December 2025
		(Rupees)	
EQUITY AND LIABILITIES			
Share capital and reserves			
Authorized share capital			
100,000,000 (December 31, 2025: 100,000,000)			
Ordinary shares of Rs. 10 each		1,000,000,000	1,000,000,000
Issued, subscribed and paid up share capital	15	529,833,630	529,833,630
Capital reserve			
Surplus on revaluation of property, plant and equipment		1,016,595,230	1,041,210,488
Revenue reserves		12,271,373,337	12,181,933,023
Total Equity		13,817,802,197	13,752,977,141
LIABILITIES			
Non-current liabilities			
Lease liabilities		370,388,349	380,821,593
Long term loan - secured	16	231,956,795	2,423,493
Deferred tax liabilities		217,551,311	250,433,156
Deferred liabilities		146,461,960	145,253,907
		966,358,415	778,932,149
Current liabilities			
Trade and other payables		3,246,216,446	3,066,846,080
Contract liabilities		48,480,173	236,624,569
Unclaimed dividend		413,325,468	304,559,821
Current portion of long term liabilities		157,043,475	117,974,112
Short term borrowings		292,866,838	301,798,222
Taxation - net		816,189,754	876,942,956
		4,974,122,154	4,904,745,760
TOTAL EQUITY AND LIABILITIES		19,758,282,766	19,436,655,050
CONTINGENCIES AND COMMITMENTS	17		

The annexed notes from 1 to 29 form an integral part of these consolidated financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Profit or Loss (Un Audited)

For The Nine Months Ended 30 September 2026

	Note	Nine Months Ended 30 September 2026	Nine Months Ended 30 September 2025	Quarter ended 30 September 2026	Quarter ended 30 September 2025
		----------(Rupees) ---------		----------(Rupees) ---------	
Revenue from contracts with customers- net	18	21,490,966,951	20,303,535,064	7,507,514,982	7,118,456,469
Cost of revenue	19	(9,138,227,268)	(9,105,173,204)	(3,219,832,321)	(3,131,785,320)
Gross profit		12,352,739,683	11,198,361,860	4,287,682,661	3,986,671,149
Distribution, selling and promotional expenses		(6,066,720,772)	(5,749,295,626)	(2,027,784,086)	(2,125,588,729)
Administrative and general expenses		(1,285,509,040)	(1,201,854,957)	(468,968,617)	(439,552,054)
Other operating expenses		(469,938,887)	(231,960,070)	(178,991,949)	(41,514,029)
		(7,822,168,699)	(7,183,110,653)	(2,675,744,652)	(2,606,654,812)
Profit from operations		4,530,570,984	4,015,251,207	1,611,938,009	1,380,016,337
Other income	20	279,034,025	323,970,885	117,929,886	94,859,640
Finance costs		(78,957,222)	(101,030,033)	(25,814,510)	(41,766,847)
Profit before income tax and levy		4,730,647,787	4,238,192,059	1,704,053,385	1,433,109,130
Levy		-	-	-	-
Profit before income tax		4,730,647,787	4,238,192,059	1,704,053,385	1,433,109,130
Taxation	21	(2,016,654,581)	(1,557,640,813)	(773,233,132)	(487,947,018)
Profit after tax for the period		2,713,993,206	2,680,551,246	930,820,253	945,162,112
Earnings per share - basic and diluted	22	51.22	50.59	17.57	17.84

The annexed notes from 1 to 29 form an integral part of these consolidated financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Comprehensive Income (Un Audited)

For The Nine Months Ended 30 September 2026

	Nine Months Ended 30 September		Quarter ended 30 September	
	2026	2025	2026	2025
	------(Rupees) ------		------(Rupees) ------	
Profit after tax for the period	2,713,993,206	2,680,551,246	930,820,253	945,162,112
Other comprehensive income				
Items that will be reclassified subsequently to statement of profit or loss	-	-	-	-
Items that will not be reclassified subsequently to statement of profit or loss	-	-	-	-
Total comprehensive income for the period	2,713,993,206	2,680,551,246	930,820,253	945,162,112

The annexed notes from 1 to 29 form an integral part of these consolidated financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Cash Flows (Un Audited)

For The Nine Months Ended 30 September 2026

	Note	Nine Months Ended 30 September 2026	2025
		----------(Rupees) ----------	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	23	4,913,261,489	2,413,888,324
Gratuity paid		(17,700,134)	(616,901,796)
Finance cost paid		(132,702,787)	(101,030,033)
Central Research Fund paid		(72,007,439)	-
Workers' Profit Participation Fund paid		(10,205,067)	-
Workers' Welfare Fund paid		(89,714,798)	(81,798,187)
Income tax paid		(2,110,289,628)	(999,709,470)
		(2,432,619,853)	(1,799,439,486)
Net cash generated from operating activities	A	2,480,641,636	614,448,838
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(911,978,833)	(618,274,235)
Purchase of intangible assets		-	(10,207,638)
Long term deposits - net		(78,584,968)	(23,818,102)
(Increase) / Decrease in long term advances		8,699,440	16,297,639
Short term investments - net		1,082,594,572	2,270,524,235
Dividend income on short term investments		13,102,694	10,676,633
Proceeds from disposal of operating fixed assets		145,345,158	117,014,365
Net cash flows (used in) / generated from investing activities	B	259,178,063	1,762,212,897
CASH FLOWS FROM FINANCING ACTIVITIES			
Lease liabilities-net		12,951,482	180,601,292
Long term loan - net		258,054,370	(440,422,222)
Dividend paid		(2,540,402,503)	(2,024,851,217)
Net cash flows used in financing activities	C	(2,269,396,651)	(2,284,672,147)
Net increase in cash and cash equivalents	(A+B+C)	470,423,048	91,989,588
Cash and cash equivalents at beginning of the period		282,427,684	709,517,074
Cash and cash equivalents at end of the period	14.2	752,850,732	801,506,662

The annexed notes from 1 to 29 form an integral part of these consolidated financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Condensed Interim Consolidated Statement of Changes in Equity (Un Audited)

For The Nine Months Ended September 30, 2026

	Share capital	Capital Reserves	Revenue reserves			Total
		Revaluation Surplus on operating fixed assets	General reserve	Unappropriated profits	Sub total	
	---------- Rupees ----------					
Balance as at January 01, 2025 - (audited)	529,833,630	1,077,558,758	114,000,000	10,073,737,871	10,187,737,871	11,795,130,259
Transaction with owners, recorded directly in equity						
Final dividend @ Rs. 40 per share for the year ended December 31, 2024	-	-	-	(2,119,334,520)	(2,119,334,520)	(2,119,334,520)
Total comprehensive income for the nine months ended September 30, 2025						
Profit for the period	-	-	-	2,680,551,246	2,680,551,246	2,680,551,246
Other comprehensive income for the period	-	-	-	-	-	-
	-	-	-	2,680,551,246	2,680,551,246	2,680,551,246
Surplus transferred to unappropriated profit						
Incremental depreciation relating to surplus on revaluation - net of tax	-	(27,261,201)	-	27,261,201	27,261,201	-
Balance as at September 30, 2025 - (un-audited)	529,833,630	1,050,297,557	114,000,000	10,662,215,798	10,776,215,798	12,356,346,985
Balance as at January 01, 2026 - (audited)	529,833,630	1,041,210,488	114,000,000	12,067,933,023	12,181,933,023	13,752,977,141
Transaction with owners, recorded directly in equity						
Final dividend @ Rs. 50 per share for the year ended December 31, 2025	-	-	-	(2,649,168,150)	(2,649,168,150)	(2,649,168,150)
Total comprehensive income for the nine months ended September 30, 2026						
Profit for the period	-	-	-	2,713,993,206	2,713,993,206	2,713,993,206
Other comprehensive income for the period	-	-	-	-	-	-
	-	-	-	2,713,993,206	2,713,993,206	2,713,993,206
Surplus transferred to accumulated profit						
Incremental depreciation relating to surplus on revaluation - net of tax	-	(24,615,258)	-	24,615,258	24,615,258	-
Balance as at September 30, 2026 - (un-audited)	529,833,630	1,016,595,230	114,000,000	12,157,373,337	12,271,373,337	13,817,802,197

The annexed notes from 1 to 29 form an integral part of these consolidated financial statements.

Dr. Adeel Abbas Haideri
Chief Executive Officer

Taufiq Ahmed Khan
Director

Ashfaq Alidina
Chief Financial Officer

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

1 LEGAL STATUS AND NATURE OF BUSINESS

The Highnoon Group (the Group) comprises of Highnoon Laboratories Limited (the Holding Company) and Curexa Health (Private) Limited (the Subsidiary Company).

The Holding Company was incorporated in Pakistan under under the Companies Ordinance, 1984 (repealed with the enactment of the Companies Act, 2017) (the Act) and its shares are quoted on Pakistan Stock Exchange since November 1994. The Holding Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and allied consumer products.

The Subsidiary Company was incorporated with the principle object to carry on business as manufacturer, importer and dealers of all kinds of pharmaceutical.

2 GEOGRAPHICAL LOCATION AND ADDRESSES OF BUSINESS UNITS

The registered office of the Group is situated at 17.5 KM , Multan Road, Lahore.

Geographical location and addresses of major business units of the Group are as under:

Business Units	Geographical Location	Address
Manufacturing facility	Lahore	17.5 KM, Multan Road, Lahore.
Subsidiary registered office / Manufacturing facility	Lahore	517- Sundar Industrial Estate, Raiwind, Lahore.
Corporate Office	Lahore	Office# 901 Tricon Corporate Centre, Jail Road, Lahore.
Sales office	Karachi	202 Anam Empire, Block 7/8 KCHS,Shahrah e Faisal, Karachi.
Sales office	Lahore	14-G, Block L, Gulberg - III, Lahore.

3 BASIS OF PREPARATION

3.1 Statement of compliance

These consolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. These accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34 - Interim Financial Reporting, issued by the International Accounting Standard Board (IASB) as notified under the Companies Act, 2017;
- Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan as notified under the Companies Act , 2017; and
- Provisions of, directives and notifications issued under the Companies Act, 2017.

Where provisions of, directives and notifications issued under the Companies Act, 2017 differ from the IFRS Accounting Standards, the provisions of, directives and notifications issued under the Companies Act, 2017 have been followed.

These consolidated condensed interim financial statements are un-audited and are being submitted to the shareholders as required under section 237 of the Companies Act, 2017 and the listing regulations of the Pakistan Stock Exchange.

These consolidated condensed interim financial statements do not include all the information and disclosures required for full annual financial statements and should be read in conjunction with the annual financial statements of the Group as at and for the year ended December 31, 2025 which have been prepared in accordance with approved accounting standards as applicable in Pakistan. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements.

The comparative statement of financial position presented in these consolidated condensed interim financial statements have been extracted from the annual audited financial statements of the Group for the year ended December 31, 2025, whereas the comparative consolidated condensed interim statement of profit or loss, consolidated condensed interim statement of comprehensive income, consolidated condensed interim statement of cash flows and consolidated condensed interim statement of changes in equity are extracted from the unaudited consolidated condensed interim financial statements for the nine months ended September 30, 2025.

3.2 Basis of measurement

The consolidated condensed interim financial statements have been prepared under the historical cost convention, except for certain classes of operating fixed assets (as mentioned in consolidated financial statements of the Group for the year ended December 31, 2025) and certain employees' retirement benefits which are measured at revalued amounts and present value, respectively.

These financial statements are the consolidated financial statements of the Group in which investment in subsidiary is accounted for on the basis of acquisition method. Standalone financial statements of the Holding Company and its Subsidiary are presented separately.

3.3 Functional and presentation currency

These consolidated condensed interim financial statements are presented in Pak rupee (Rupee), which is also the functional currency of the Group.

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

4 APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS TO PUBLISHED APPROVED ACCOUNTING AND REPORTING STANDARDS

4.1 Amendments to published accounting and reporting standards which became effective during the period:

Certain standards, amendments and interpretations to approved accounting standards are effective for accounting periods beginning on January 01, 2026, but are considered not to be relevant or to have any significant effect on the Group's operations (although they may affect the accounting for future transactions and events) and are, therefore, not detailed in these consolidated condensed interim financial statements.

4.2 Standards, amendments and interpretations to existing standards that are not yet effective and have not been early adopted by the Group:

There are certain standards, amendments to the accounting standards and interpretations that are mandatory for the Group's accounting periods beginning on or after January 1, 2026, but are considered not to be relevant or expected to have any significant effect on the Group's operations except as follows:

IFRS 18 Presentation and Disclosure in Financial Statements, which was issued by the IASB in April 2024 supersedes IAS 1 and will result in major consequential amendments to IFRS Accounting Standards including IAS 8 Basis of Preparation of Financial Statements (renamed from Accounting Policies, Changes in Accounting Estimates and Errors). Even though IFRS 18 will not have any effect on the recognition and measurement of items in the financial statements, it is expected to have a significant effect on the presentation and disclosure of certain items. These changes include categorisation and sub-totals in the statement of profit or loss, aggregation/disaggregation and labelling of information, and disclosure of management-defined performance measures.

5 MATERIAL ACCOUNTING POLICIES INFORMATION

The accounting policies adopted in the preparation of these consolidated condensed interim financial statements are consistent with those followed in the preparation of the Group's annual financial statements for the year ended December 31, 2025 execpt otherwise stated in these consolidated condensed interim financial statements.

6 TAXATION AND OTHERS

6.1 The provisions for taxation for the nine months and quarter ended September 30, 2026, have been made using the estimated effective tax rate applicable to expected total annual earnings. The applicable income tax rate for the Tax Year 2026 is 29% plus super tax. Income tax expense is recognized in each interim period based on best estimate of the weighted average annual income tax rate expected for the full financial year.

Amounts accrued for income tax expense in one interim period may have to be adjusted in a subsequent interim period of that financial year if the estimate of the annual income tax rate changes.

Provisions in respect of Workers' Welfare Fund and Workers' Profit Participation Fund are estimated based on management judgment and prevailing laws; these are subject to final adjustments in the annual audited financial statements.

7 USE OF ESTIMATES AND JUDGEMENTS

The preparation of these consolidated condensed interim financial statements, in conformity with accounting and reporting standards as applicable in Pakistan requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Actual results may differ from the estimates. During the preparation of these consolidated condensed interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation and assumptions are consistent with those that were applied to the audited financial statements of the Group for the year ended December 31, 2025.

8 FINANCIAL RISK MANAGEMENT

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, interest rate risk and price risk), credit risk and liquidity risk.

There have been no significant changes in the risk management policies since the year end.

The consolidated condensed interim financial statements does not include all financial risk management information and disclosures required in the annual financial statements and should be read in conjunction with the Group's audited annual financial statements for the year ended December 31, 2025.

The Group's financial risk management objective and policies are consistent with that disclosed in the consolidated annual financial statements for the year ended December 31, 2025.

		Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			----------(Rupees) ----------	
9	PROPERTY, PLANT AND EQUIPMENT			
	Operating fixed assets	9.1	3,802,185,677	3,563,700,192
	Right of use assets	9.2	585,849,460	557,996,242
			4,388,035,137	4,121,696,434
	Capital work-in-progress		470,084,871	278,085,356
	Advances against capital assets		2,210,443	785,000
			4,860,330,451	4,400,566,790

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

		Note	September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			----------(Rupees) ----------	
9.1	Owned assets			
	Opening book value		3,563,700,192	3,624,780,882
	Additions during the period / year	9.1.1	572,446,052	328,424,502
			4,136,146,244	3,953,205,384
	Disposals during the period / year	9.1.2	(96,632,991)	(50,158,263)
	Depreciation for the period / year		(237,327,576)	(339,346,929)
			(333,960,567)	(389,505,192)
	Closing book value		3,802,185,677	3,563,700,192
9.1.1	Additions during the period / year - cost			
	Building on freehold land		101,275,679	38,116,607
	Leasehold improvement		-	45,895,314
	Plant and machinery		309,951,653	142,014,471
	Laboratory equipment		54,646,470	21,407,059
	Furniture and fixture		4,436,310	9,168,367
	Electric and gas appliances		17,573,098	4,163,431
	Office equipment		32,231,504	34,096,875
	Vehicles		52,331,338	33,562,378
			572,446,052	328,424,502
9.1.2	Disposals during the period / year			
	Laboratory equipment		-	140,298
	Furniture & Fixtures		30,793	-
	IT and office equipment		3,955,581	1,553,533
	Vehicles		92,646,617	48,464,432
			96,632,991	50,158,263
9.2	Right of use assets			
	Opening book value		557,996,242	89,084,423
	Additions / transfer during the period / year - cost		146,107,823	590,509,302
			704,104,065	679,593,725
	Disposal / transferred to owned assets		(40,521,933)	(43,161,656)
	Depreciation for the period / year		(77,732,672)	(78,435,827)
			(118,254,605)	(121,597,483)
	Closing book value		585,849,460	557,996,242
10	LONG-TERM LOANS AND ADVANCES			
	Secured - considered good			
	Loan to employees - secured	10.1	63,028,963	66,815,744
	Less: current portion		(17,307,017)	(12,394,358)
			45,721,946	54,421,386

10.1 These represent loan given to employees against the purchase of vehicles as per the Group's policy. These loans are for maximum period of 5 years. These loans are secured against the final settlement amount of employees. The loans carry an effective interest rate of 0% (2025: 0%) per annum and are repayable in cash in accordance with predefined repayment schedule. The impact of discounting to present value is assessed to be immaterial by the management.

			September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			----------(Rupees) ----------	
11	INVENTORIES			
	Raw materials			
	In hand		2,636,278,228	2,895,773,291
	In transit		413,621,853	453,265,870
	With third party		203,440,345	135,911,573
			3,253,340,426	3,484,950,734
	Packing material			
	In hand		987,557,995	786,072,374
	With third party		20,297,276	25,046,346
			1,007,855,271	811,118,720
	Stores, spare parts and loose tools		238,816,064	183,851,002
	Work in progress		457,041,897	555,862,103
	Finished goods			
	Trading - in hand		545,463,175	246,760,736
	Manufactured		487,810,828	634,506,634
			1,033,274,003	881,267,370
	Provision for slow moving and obsolete items	11.1	(153,711,736)	(203,208,590)
			5,836,615,925	5,713,841,339
11.1	Provision for slow moving and obsolete items:			
	Opening balance		203,208,590	212,150,560
	Charge for the period / year		84,331,699	75,051,310
	Write-off for the period / year		(133,828,553)	(83,993,280)
	Closing provision		153,711,736	203,208,590

11.1.1 The Group has revised its accounting estimate relating to the provision for slow-moving raw materials. Effective during the current period, the provision rate for raw materials with a remaining shelf life of six months has been reduced from 100% to 50%, based on prevailing industry practice and management's assessment of the expected utilization of such materials.

Had there been no change in the accounting estimate, the provision for slow-moving raw materials for the current period would have been higher by Rs. 29.660 million.

			September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			----------(Rupees) ----------	
12	TRADE RECEIVABLES			
	Export sales		211,281,933	165,891,286
	Local sales		4,468,235,104	4,364,914,736
			4,679,517,037	4,530,806,022
	Less: allowance for expected credit losses	12.1	(214,517,644)	(129,957,454)
			4,464,999,393	4,400,848,568
12.1	Allowance for expected credit losses:			
	Opening balance		129,957,454	57,651,504
	Charge during the period / year		84,560,190	72,305,950
			214,517,644	129,957,454
13	SHORT-TERM INVESTMENTS			
	Investments at fair value through profit or loss			
	Mutual funds - fair value through profit and loss	13.1	850,807,844	2,659,250,468
	Term deposit receipts - at amortization cost	13.2	1,143,649,466	400,372,214
			1,994,457,310	3,059,622,682
13.1	These investments are measured at fair value through profit or loss:			
	Balance at the beginning of the period / year		2,659,250,468	3,471,920,933
	Additions during the period / year		2,370,000,000	6,133,140,049
	Redemption during the period / year		(4,351,818,294)	(7,290,579,760)
	Realized gain on redemption of investment during the period / year		155,946,470	168,760,287
	Un-realized (loss) / gain on remeasurement of investments during the period / year		17,429,200	176,008,959
	Closing fair value of short-term investments		850,807,844	2,659,250,468

13.2 These represent investments in term deposit receipts. They carry average profit at the rate of ranging from 9.02% to 11.25% per annum (2025: 9.02% to 16% per annum) with maturity up to November 2026.

			September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			----------(Rupees) ----------	
14	CASH AND BANK BALANCES			
	Cash in hand		601,341	399,622
	Balance with banks			
	Current accounts			
	- Local currency		351,493,661	203,826,885
	- Foreign currency		243,701,597	228,704,609
	Savings accounts	14.1	449,920,971	151,294,790
	Saving accounts		1,045,116,229	583,826,284
			1,045,717,570	584,225,906

14.1 These represents savings accounts which carries average profit at the rate of ranging from 6.46% to 9.10% per annum (2025: 6.46% to 9.10% per annum).

		September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
		----------(Rupees) ----------	
14.2	Cash and cash equivalents		
	Cash and bank balances	1,045,717,570	584,225,906
	Short term borrowings	(292,866,838)	(301,798,222)
		752,850,732	282,427,684

15	ISSUED, SUBSCRIBED AND PAID UP SHARE CAPITAL		
	5,905,000 (December 31, 2025: 5,905,000) ordinary shares of Rs. 10 each fully paid in cash	59,050,000	59,050,000
	95,000 (December 31, 2025: 95,000) ordinary shares of Rs.10 each issued for consideration other than cash	950,000	950,000
	46,983,363 (December 31, 2025: 46,983,363) ordinary shares of Rs. 10 each issued as bonus shares	469,833,630	469,833,630
		529,833,630	529,833,630

16	LONG-TERM LOAN - SECURED		
	Long-term loan	245,983,251	6,319,789
	Less: Current portion shown under current liabilities	(14,026,456)	(3,896,296)
		231,956,795	2,423,493

			September 30, 2026 (Un-audited)	December 31, 2025 (Audited)
			----------(Rupees) ----------	
16.1	The movement of long-term loan is as follows:			
	Opening balance as at January 01,	16.1.1 & 16.1.2	6,319,789	447,716,085
	Loan obtained during the period / year		242,585,684	-
	Principal payments made during the period / year		(2,922,222)	(441,396,296)
			245,983,251	6,319,789
	Current portion shown under current liabilities		(14,026,456)	(3,896,296)
	Closing balance		231,956,795	2,423,493

16.1.1 This includes loan obtained from MCB Bank Limited with maturity date of June 10, 2029 under facility for setting up solar based power project under SBP financing scheme for renewable energy having sanctioned limit of Rs. 50 million (2025: Rs. 50 million) and carries markup at the rate of 2% + 0.5% per annum payable quarterly (2025: 2% + 0.5%) whereas principal is repayable in 27 equal quarterly instalments starting from December 10, 2022. This facility is secured against lien on mutual funds up to Rs. 67 million placed in MCB Investment Management Limited. The loan has been measured at its fair value in accordance with IFRS 9 (Financial Instruments) using effective interest rate of 3 months KIBOR at respective draw down date.

16.1.2 The Group has obtained long-term Shariah-compliant term financing facility from Meezan Bank Limited with total limits of PKR 500 million for capital expenditure and BMR requirements. The facilities comprise SBP LTFF and commercial terms, carry markup ranging from SBP Base Rate - 3.00% per annum (with a 5% floor and 35% cap), a 5-year tenure including a 1-year grace period and eight equal semi-annual repayments. The facilities are secured by a 1st Pari Passu charge on all present and future plant and machinery of the Group with a 25% margin.

16.2 The difference between fair value of loan and loan proceeds has been recognised as deferred grant as per requirements of IAS 20 (Accounting for Government grants and disclosure of Government assistance) and as per circular 11/2020 issued by the Institute of Chartered Accountants of Pakistan.

17 CONTINGENCIES AND COMMITMENTS

17.1 Contingencies

There have been no significant changes in contingencies as reported in the annual audited consolidated financial statements of the Group for the year ended December 31, 2025 except following:

17.1.1 The Assistant / Deputy Commissioner Inland Revenue has issued an order under sections 205 read with 137(1) of the Income Tax Ordinance, 2001, in respect of Tax Year 2023, creating a demand of Rs. 56.05 million on account of default surcharge due to failure of full discharge of liability of super tax.

Being aggrieved by the said order, the Group has preferred an appeal before the Commissioner Inland Revenue (Appeals) [CIR (A)], which is pending adjudication. No provision has been recognized by the Group, as the management, based on the opinion of its tax consultants, expects a favorable outcome.

17.1.2 In respect of the contingency reported under note 30.1.8 to the audited financial statement for the year ended December 31, 2025, the Civil Originals relating to, inter alia, the related party transactions have been clubbed with the Group's Writ Petition seeking a stay of the proceedings initiated by the SECP and are presently fixed for hearing before the Lahore High Court.

In the matter concerning the rectification of shares, the Lahore High Court dismissed the petition on grounds of limitation. The plaintiffs subsequently filed a Civil Petition for Leave to Appeal (CPLA) before the Supreme Court. Thereafter, vide its order dated April 22, 2026, a regular bench of the Supreme Court remanded the matter to Lahore High Court for reconsideration along with multiple other petitions pertaining to the same issue. The Group has since then also filed a revision petition before the Supreme Court of Pakistan. The management, based on the assessment of its concerned legal advisors, is of the view that no outflow of economic resources is expected to occur based on the aforementioned petition.

The Group is actively pursuing the above matters at respective forums. Based on the advice of the legal counsel, the Group is hopeful for the favorable outcome of the matters. Hence, no provision has been made in these financial statements.

		Note	Un Audited 30 September 2026	Audited 31 December 2025
			--------(Rupees) --------	
17.2	Commitments			
	The Group has commitments against:			
	Letter of credit		974,510,555	956,401,169
	Bank contracts		295,991,244	489,730,620
	Ijarah rentals	17.2.1	726,123,030	350,131,549
	Capital work in progress		71,526,985	80,240,684
			2,068,151,814	1,876,504,022
17.2.1	Future payments under Ijarah			
	Within one year		206,041,524	87,634,402
	After one year but not more than five years		520,081,506	262,497,147
			726,123,030	350,131,549

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

18 REVENUE FROM CONTRACTS WITH CUSTOMERS- NET

18.1 Disaggregated revenue information

Set out below is the disaggregation of the Group's revenue from contracts with customers :

	Un-audited			
	Nine Months Ended 30 September		Quarter ended 30 September	
	2026	2025	2026	2025
	(Rupees)			
Manufacturing:				
Local	22,559,395,515	20,158,735,163	8,577,369,012	6,930,402,948
Export	664,341,495	1,536,117,458	295,174,582	676,015,467
	23,223,737,010	21,694,852,621	8,872,543,594	7,606,418,415
Trading	3,843,373,050	2,159,877,623	1,449,681,207	709,032,254
Toll manufacturing	653,894,469	614,707,380	273,002,786	243,504,514
Less:				
Sales tax	(202,521,635)	(199,213,692)	(66,736,138)	(58,132,577)
Trade discount	(3,966,151,812)	(3,465,517,127)	(1,975,638,025)	(1,146,015,074)
Sales return	(2,061,364,131)	(501,171,741)	(1,045,338,442)	(236,351,063)
	21,490,966,951	20,303,535,064	7,507,514,982	7,118,456,469

18.2 Geographical information

	Un-audited Nine Months Period Ended 30 September	
	2026	2025
	(Rupees)	
Pakistan	20,905,053,640	18,767,984,858
Afghanistan	-	1,138,469,885
Azerbaijan	5,523,310	-
Cambodia	9,427,123	18,883,757
France	134,667,118	69,098,734
Iraq	114,324,841	116,763,815
Kenya	54,753,725	37,024,249
Mauritius	7,152,320	2,121,816
Myanmar	2,314,743	-
Sierra Leone	610,060	-
Somalia	65,097,806	51,413,962
Sri Lanka	90,759,212	70,701,337
Sudan	70,584,223	11,495,219
Tanzania	6,438,921	-
Turkmenistan	19,655,584	14,260,472
Zambia	4,604,325	5,316,960
	21,490,966,951	20,303,535,064

		Un-audited			
		Nine Months Ended 30 September		Quarter ended 30 September	
		2026	2025	2026	2025
		(Rupees)			
19.	COST OF REVENUE				
	Opening stock of finished goods	881,267,370	876,576,503	1,218,513,206	563,731,499
	Cost of goods manufactured	7,333,539,157	8,094,333,342	2,432,160,056	3,012,864,484
	Purchased finish products	1,956,694,744	841,042,708	602,433,062	261,968,686
	Available stock for sale	10,171,501,271	9,811,952,553	4,253,106,324	3,838,564,669
	Closing stock of finished goods	(1,033,274,003)	(706,779,349)	(1,033,274,003)	(706,779,349)
	Cost of revenue	9,138,227,268	9,105,173,204	3,219,832,321	3,131,785,320

		Note	Un-audited Nine Months Period Ended 30 September	
			2026	2025
			(Rupees)	
20.	OTHER INCOME			
	Return on deposits and mark-up on interest bearing accounts		70,825,643	30,538,477
	Dividend income on short term investment		13,102,694	10,676,633
	Unrealized gain on re-measurement of short term investment to fair value		17,429,200	153,779,760
	Realized gain on short term investment		155,112,586	84,043,829
	Exchange gain - net		4,621,426	2,066,989
	Royalty income from associate	20.1	4,333,383	5,662,200
	Deferred income		2,602,914	-
	Gain on disposal of operating fixed asset		8,190,234	35,502,805
	Scrap sales		1,587,633	1,697,540
	Other income		1,228,312	2,652
			279,034,025	323,970,885

20.1 This represents royalty income from Route 2 Health (Private) Limited, at the rates of 2.5% of net sales.

		Note	Un-audited Nine Months Ended 30 September 2026	2025
			----------(Rupees) ---------	
21	TAXATION-NET			
	Current tax			
	-current period		1,879,175,772	964,158,249
	-prior period	21.1 & 21.2	170,360,654	670,190
			2,049,536,426	964,828,439
	Deferred tax		(32,881,845)	104,865,356
			2,016,654,581	1,069,693,795

21.1 This includes tax payments amounting to Rs. 16.896 million made against demands raised for Tax Years 2019, 2021, and 2022.

21.2 On January 27, 2026, Federal Constitutional Court upheld the legality of the Super Tax under Sections 4B and 4C of the Income Tax Ordinance 2001, ruling it constitutional and enforceable. Pursuant to passing of the order company has recognized super tax provision amounting to Rs. 153.464 million for financial year 2022 and 2023:

		Un-audited			
		Nine Months Period Ended 30 September		Quarter ended 30 September	
		2026	2025	2026	2025
		---------- (Rupees) ----------			
22	EARNINGS PER SHARE				
	Profit for the period - (Rupees)	2,713,993,206	2,680,551,246	930,820,253	945,162,112
	Weighted average number of ordinary sharesoutstanding during the period - (Numbers)	52,983,363	52,983,363	52,983,363	52,983,363
	Basic and diluted - (Rupees)	51.22	50.59	17.57	17.84

		Note	(Un-audited) Nine Months Ended 30 September 2026	2025
			----------(Rupees)--- ------	
23.	CASH FLOWS FROM OPERATING ACTIVITIES			
	Profit before income tax and levy		4,730,647,787	4,238,192,059
	Adjustments for non-cash and other items:			
	Depreciation of operating fixed assets	9.1	315,060,248	265,049,837
	Amortization of intangible assets		13,031,256	11,290,984
	Provision for defined benefit obligation		6,071,755	376,528,691
	Provision for slow moving and obsolete stocks	11	(49,496,854)	7,685,497
	Provision for Workers' Profit Participation Fund		256,407,687	216,175,371
	Provision for Workers Welfare Fund		102,563,074	81,643,395
	Provision for Central Research Fund		51,281,538	37,970,119
	Finance cost		150,330,429	101,030,033
	Exchange gain - net		(4,621,426)	(2,066,989)
	Gain on disposal of property plant and equipment	20	(8,190,234)	(35,502,805)
	Un-realized gain on remeasurement of investments	20	(17,429,200)	-
	Dividend income on short term investment	20	(13,102,694)	(10,676,633)
	Allowance for expected credit loss		84,560,190	-
			886,465,769	1,049,127,500
	Cash flow before working capital changes		5,617,113,556	5,287,319,559
	Working capital changes:			
	(Increase) / decrease in current assets:			
	Inventories		(73,277,732)	(1,333,581,295)
	Trade debts		(144,089,589)	(1,658,129,448)
	Advances, trade deposits and prepayments		(59,988,444)	(480,210,261)
	Other receivables		(69,424,259)	103,121,676
	Tax refunds due from the Government		(92,345,376)	(93,504,125)
	Increase / (decrease) in current liabilities:			
	Trade and other payables		(76,582,271)	535,421,526
	Contract liabilities		(188,144,396)	53,450,692
			(703,852,067)	(2,873,431,235)
	Cash generated from operations		4,913,261,489	2,413,888,324

Notes to the Condensed Interim Consolidated Financial Statements (Un Audited)

For The Nine Months Ended 30 September 2026

24. BALANCES AND TRANSACTIONS WITH RELATED PARTIES

The related parties of the Group comprise associated companies, companies in which directors are interested, staff retirement funds and directors and key management personnel. The transactions with related parties are carried out under the related party transactions policy approved by the Board of Directors of the Group. Details of transactions with related parties and balances with them at period end, other than those which have been disclosed elsewhere in these financial statements, are as follows:

24.1 Transactions during the period:

Name of related party	Relationship	Nature of transaction	(Un-audited) Nine Months Ended 30 June 2026	2025
			-------Rupees)-------	
Route 2 health (Private) Limited	Associate (Common directorship and shareholder of 0.45% (2025:0.45%)	Sales during the period - net	-	115,296,184
		Royalty Income	4,333,383	5,662,200
		Receipts during the period	4,333,383	127,201,616
		Dividend paid	11,903,950	9,523,160
Pharmatec Investments Limited	Associate (Common control and shareholder of 8.34% (2025:8.34%)	Dividend paid	220,812,100	176,649,680
Highnoon Laboratories Limited	Staff retirement fund	Contribution to provident fund	179,349,328	144,196,455
Staff Provident Fund		Dividend paid	10,677,500	8,542,000
Highnoon Laboratories Limited	Staff welfare trust	Contribution to staff welfare trust	6,278,235	5,454,072
Staff Welfare Trust		Dividend paid	6,148,250	7,860,680

24.2 Balance outstanding as at reporting date:

Name of related party	Relationship	Nature of transaction	September 30, 2026 (Unaudited) 2026	December 31, 2025 (Audited) 2025
			------(Rupees)-----	
Highnoon Laboratories Limited Staff Provident Fund	Staff retirement funds	Payable to provident fund	30,519,469	19,974,618
Highnoon Laboratories Limited Staff Welfare Trust	Staff welfare trust	Payable to staff welfare trust	1,791,667	1,030,236

24.3 Transactions with key management personnel under the terms of employment are excluded from related party transactions.

25 EVENTS AFTER THE REPORTING DATE

These are no significant reportable event after the consoldiated condensed interim statement of financial position

26 CORRESPONDING FIGURES

26.1 Corresponding figures have been re-arranged or reclassified wherever necessary, for better and fair presentation. However no significant rearrangement / reclassification has been made during the period.

This has been merged with administrative and general expenses as per industry practice, as there was no research and development activity.

26.2 In order to comply with the requirements of International Accounting Standard 34 - 'Interim Financial Reporting', corresponding figures in the consolidated condensed interim statement of financial position comprise of balances as per the audited annual financial statements of the Group for year ended December 31, 2025 and the corresponding figures in the consolidated condensed interim statement of profit or loss and the consolidated condensed interim comprehensive income, consolidated condensed interim statement of cash flows and consolidated condensed interim statement of changes in equity comprise of balances of comparable period as per the consolidated condensed interim financial statements of the Group for the nine months ended September 30, 2025.

27 SEGMENT REPORTING

The chief operating decision maker (i.e. the Board of Directors) considers the whole business as one operating segment.

28 DATE OF AUTHORIZATION OF ISSUE

The Board of Directors of the Group authorized these consolidated financial statements for issuance on October 27, 2026.

29 GENERAL

The figures in these consolidated financial statements are rounded off to the nearest rupee, unless otherwise stated.

Dr. Adeel Abbas Haideri	Taufiq Ahmed Khan	Ashfaq Alidina
Chief Executive Officer	Director	Chief Financial Officer

Enriching Life





Highnoon

Address : 17.5 KM, Multan Road,
Lahore - 53700, Pakistan.
UAN : +92 (42) 111-000-465
Phone : +92 (42) 37510023-27
Fax : +92 (42) 37510037
Email : info@highnoon.com.pk
Web : www.highnoon-labs.com